[HTML][HTML] Immune-checkpoint inhibitors: long-term implications of toxicity
The development of immune-checkpoint inhibitors (ICIs) has heralded a new era in cancer
treatment, enabling the possibility of long-term survival in patients with metastatic disease …
treatment, enabling the possibility of long-term survival in patients with metastatic disease …
Immune checkpoint inhibitors in melanoma
Immune checkpoint inhibitors target the dysfunctional immune system, to induce cancer-cell
killing by CD8-positive T cells. Immune checkpoint inhibitors, specifically anti-CTLA4 and …
killing by CD8-positive T cells. Immune checkpoint inhibitors, specifically anti-CTLA4 and …
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
ILM Reijers, AM Menzies, ACJ Van Akkooi… - Nature medicine, 2022 - nature.com
Neoadjuvant ipilimumab and nivolumab induces high pathologic response rates (pRRs) in
clinical stage III nodal melanoma, and pathologic response is strongly associated with …
clinical stage III nodal melanoma, and pathologic response is strongly associated with …
[HTML][HTML] Clinical challenges of immune checkpoint inhibitors
M de Miguel, E Calvo - Cancer cell, 2020 - cell.com
Even though the immuno-oncology (IO) era has achieved many successes, some signs of
research development deceleration are arising. Recently, the number of FDA …
research development deceleration are arising. Recently, the number of FDA …
Continuous versus 1-year fixed-duration nivolumab in previously treated advanced non–small-cell lung cancer: CheckMate 153
DM Waterhouse, EB Garon, J Chandler… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE Limited data exist on the optimal duration of immunotherapy, including for non–
small-cell lung cancer (NSCLC). We present an exploratory analysis of CheckMate 153, a …
small-cell lung cancer (NSCLC). We present an exploratory analysis of CheckMate 153, a …
The cutting-edge progress of immune-checkpoint blockade in lung cancer
F Zhou, M Qiao, C Zhou - Cellular & molecular immunology, 2021 - nature.com
Great advances in immune checkpoint blockade have resulted in a paradigm shift in patients
with lung cancer. Immune-checkpoint inhibitor (ICI) treatment, either as monotherapy or …
with lung cancer. Immune-checkpoint inhibitor (ICI) treatment, either as monotherapy or …
Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
The gut microbiota modulates immune processes both locally and systemically. This
includes whether and how the immune system reacts to emerging tumours, whether …
includes whether and how the immune system reacts to emerging tumours, whether …
[HTML][HTML] ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee
U Keilholz, PA Ascierto, R Dummer, C Robert… - Annals of oncology, 2020 - Elsevier
Highlights•A melanoma consensus conference, organised by the ESMO Guidelines
Committee, was attended by 32 experts from 14 countries•The experts compiled …
Committee, was attended by 32 experts from 14 countries•The experts compiled …
[HTML][HTML] Optimizing the dose and schedule of immune checkpoint inhibitors in cancer to allow global access
I Hirsch, DA Goldstein, IF Tannock, MO Butler… - Nature Medicine, 2022 - nature.com
Immune checkpoint inhibitors such as pembrolizumab or nivolumab, which inhibit PD-1,
have greatly improved survival for many patients with cancer, but are prohibitively expensive …
have greatly improved survival for many patients with cancer, but are prohibitively expensive …
Long-term outcomes and responses to retreatment in patients with melanoma treated with PD-1 blockade
A Betof Warner, JS Palmer, AN Shoushtari… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE To analyze long-term outcomes after treatment discontinuation of anti–
programmed death-1 (anti–PD-1) therapy in a cohort of patients with melanoma with the …
programmed death-1 (anti–PD-1) therapy in a cohort of patients with melanoma with the …